Case and Research Letter
Unresectable Angiosarcoma Treated With Bevacizumab and Paclitaxel
Angiosarcoma irresecable tratado con bevacizumab y paclitaxel
Leído
7914
Vecesse ha leído el artículo
2316
Total PDF
5598
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 101 | 3 | 104 |
| 2025 5 | 160 | 25 | 185 |
| 2025 4 | 146 | 38 | 184 |
| 2025 3 | 137 | 19 | 156 |
| 2025 2 | 139 | 28 | 167 |
| 2025 1 | 112 | 34 | 146 |
| 2024 12 | 125 | 36 | 161 |
| 2024 11 | 149 | 66 | 215 |
| 2024 10 | 108 | 57 | 165 |
| 2024 9 | 98 | 30 | 128 |
| 2024 8 | 114 | 36 | 150 |
| 2024 7 | 88 | 42 | 130 |
| 2024 6 | 89 | 31 | 120 |
| 2024 5 | 92 | 28 | 120 |
| 2024 4 | 79 | 34 | 113 |
| 2024 3 | 87 | 32 | 119 |
| 2024 2 | 67 | 30 | 97 |
| 2024 1 | 61 | 46 | 107 |
| 2023 12 | 64 | 100 | 164 |
| 2023 11 | 65 | 26 | 91 |
| 2023 10 | 83 | 28 | 111 |
| 2023 9 | 74 | 29 | 103 |
| 2023 8 | 57 | 11 | 68 |
| 2023 7 | 79 | 33 | 112 |
| 2023 6 | 75 | 25 | 100 |
| 2023 5 | 95 | 22 | 117 |
| 2023 4 | 49 | 18 | 67 |
| 2023 3 | 61 | 25 | 86 |
| 2023 2 | 42 | 28 | 70 |
| 2022 1 | 41 | 23 | 64 |
| 2022 12 | 47 | 40 | 87 |
| 2022 11 | 37 | 26 | 63 |
| 2022 10 | 30 | 21 | 51 |
| 2022 9 | 29 | 39 | 68 |
| 2022 8 | 23 | 29 | 52 |
| 2022 7 | 35 | 40 | 75 |
| 2022 6 | 33 | 20 | 53 |
| 2022 5 | 39 | 39 | 78 |
| 2022 4 | 47 | 39 | 86 |
| 2022 3 | 50 | 54 | 104 |
| 2022 2 | 29 | 22 | 51 |
| 2021 1 | 37 | 37 | 74 |
| 2021 12 | 29 | 28 | 57 |
| 2021 11 | 39 | 53 | 92 |
| 2021 10 | 32 | 38 | 70 |
| 2021 9 | 35 | 28 | 63 |
| 2021 8 | 34 | 31 | 65 |
| 2021 7 | 27 | 29 | 56 |
| 2021 6 | 38 | 21 | 59 |
| 2021 5 | 29 | 30 | 59 |
| 2021 4 | 52 | 35 | 87 |
| 2021 3 | 57 | 16 | 73 |
| 2021 2 | 54 | 26 | 80 |
| 2020 1 | 41 | 12 | 53 |
| 2020 12 | 33 | 14 | 47 |
| 2020 11 | 21 | 15 | 36 |
| 2020 10 | 26 | 12 | 38 |
| 2020 9 | 42 | 10 | 52 |
| 2020 8 | 29 | 17 | 46 |
| 2020 7 | 28 | 18 | 46 |
| 2020 6 | 24 | 19 | 43 |
| 2020 5 | 25 | 12 | 37 |
| 2020 4 | 27 | 16 | 43 |
| 2020 3 | 25 | 11 | 36 |
| 2020 2 | 4 | 3 | 7 |
| 2020 1 | 4 | 0 | 4 |
| 2019 12 | 8 | 1 | 9 |
| 2019 11 | 4 | 2 | 6 |
| 2019 10 | 0 | 1 | 1 |
| 2019 9 | 8 | 0 | 8 |
| 2019 8 | 4 | 4 | 8 |
| 2019 7 | 2 | 0 | 2 |
| 2019 6 | 5 | 12 | 17 |
| 2019 5 | 1 | 6 | 7 |
| 2019 4 | 0 | 10 | 10 |
| 2019 3 | 2 | 5 | 7 |
| 2019 2 | 0 | 1 | 1 |
| 2019 1 | 2 | 1 | 3 |
| 2018 12 | 0 | 1 | 1 |
| 2018 11 | 1 | 3 | 4 |
| 2018 10 | 2 | 0 | 2 |
| 2018 9 | 1 | 0 | 1 |
| 2018 6 | 0 | 1 | 1 |
| 2018 5 | 0 | 4 | 4 |
| 2018 3 | 0 | 2 | 2 |
| 2018 2 | 33 | 3 | 36 |
| 2018 1 | 26 | 6 | 32 |
| 2017 12 | 36 | 9 | 45 |
| 2017 11 | 30 | 3 | 33 |
| 2017 10 | 31 | 4 | 35 |
| 2017 9 | 50 | 3 | 53 |
| 2017 8 | 53 | 14 | 67 |
| 2017 7 | 54 | 18 | 72 |
| 2017 6 | 61 | 10 | 71 |
| 2017 5 | 58 | 11 | 69 |
| 2017 4 | 64 | 4 | 68 |
| 2017 3 | 39 | 33 | 72 |
| 2017 2 | 36 | 11 | 47 |
| 2016 1 | 29 | 9 | 38 |
| 2016 12 | 40 | 18 | 58 |
| 2016 11 | 54 | 14 | 68 |
| 2016 10 | 57 | 8 | 65 |
| 2016 9 | 71 | 11 | 82 |
| 2016 8 | 61 | 7 | 68 |
| 2016 7 | 36 | 4 | 40 |
| 2016 6 | 6 | 9 | 15 |
| 2016 5 | 5 | 2 | 7 |
| 2016 4 | 1 | 15 | 16 |
| 2016 3 | 6 | 7 | 13 |
| 2016 2 | 12 | 1 | 13 |
| 2015 1 | 12 | 4 | 16 |
| 2015 12 | 12 | 3 | 15 |
| 2015 11 | 10 | 10 | 20 |
| 2015 10 | 9 | 16 | 25 |
| 2015 9 | 8 | 6 | 14 |
| 2015 8 | 16 | 3 | 19 |
| 2015 7 | 88 | 5 | 93 |
| 2015 6 | 59 | 4 | 63 |
| 2015 5 | 49 | 9 | 58 |
| 2015 4 | 54 | 14 | 68 |
| 2015 3 | 60 | 5 | 65 |
| 2015 2 | 45 | 4 | 49 |
| 2015 1 | 32 | 7 | 39 |
| 2014 12 | 42 | 4 | 46 |
| 2014 11 | 36 | 10 | 46 |
| 2014 10 | 34 | 3 | 37 |
| 2014 9 | 32 | 8 | 40 |
| 2014 8 | 30 | 10 | 40 |
| 2014 7 | 21 | 13 | 34 |
| 2014 6 | 29 | 6 | 35 |
| 2014 5 | 3 | 1 | 4 |
Mostrar todo
